Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW856553 (Losmapimod) in COPD
NCT00392587Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing GW856553 with Placebo (2 arms). Primary endpoints: Measurements of adverse events at 14 days, Changes in heart rate at 14 days and 3 more. Started Aug 2006; status: completed.
02
Drugs
losmapimod
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00392587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00392587.